Loncastuximab

Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL) . Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349) [1][2].

Product Specifications

CAS Number

[1875032-68-0]

Product Name Alternative

RB4v1.2

UNSPSC

12352203

Target

ADC Antibody; CD19

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/loncastuximab.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Loncastuximab]

Molecular Weight

(144.46 kDa)

References & Citations

[1]Zinzani PL, et al. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2022 Jan;148 (1) :177-190. |[2]Hess B, et al. Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma. AAPS J. 2021 Dec 10;24 (1) :11.